OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)Daratumumab, when combined with PI or an IMiD increases depth of response in MM. Minimal/measurable...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. PMID: 32682484 Daratumumab in AL amyloidosis. PMID: 35507692 Daratumumab, lenalidomide, and...
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. PMID: 32682484 Daratumumab in AL amyloidosis. PMID: 35507692 Daratumumab, lenalidomide, and...
in combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma alone in people who have received at least three prior medicines, including a protea...
In our exclusive interview, Usmani discussed the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma. Related Videos Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma ...
Daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(suppl 1): 860. doi: ...
Baseline characteristics: median time since diagnosis, 4.8 y; median prior treatment lines, 5; 75% ISS ≥2. Refractory to: last line of therapy, 96%; last PI and IMiD, 95%;pomalidomide, 63%: carfilzomib, 48%; alkylating agents, 78%. Adverse events(AE; ≥ 20%) were fatigue (39.6%)...
Carfilzomib (CFZ) is a potent, second-generation proteasome inhibitor (PI), with significant activity as a single agent and in combination with other antimyeloma agents in patients with relapsed or refractory multiple myeloma (RRMM). CFZ... Monika,Engelhardt,Magdalena,... - 《Recent Results in ...
carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma alone in people who have received at least three prior medicines, including a proteasome inhibitor and an ...